Activist investor Trian Fund Management plans to push Solventum to separate more of its businesses after the company’s $4.1 ...

Thermo Fisher’s release goes on to suggest that it believes it can more than double the profitability of Purification & Filtration under its corporate umbrella, relative to the business’ current ...

Trian Fund Management, which beneficially owns about 5% of Solventum (SOLV) and is the company’s largest active shareholder, commented on ...

M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.

Investing.com -- Activist investor Trian Fund Management is reportedly planning to urge Solventum to separate additional businesses following the company’s $4.1 billion deal to sell its filtration ...

Feb 26 (Reuters) - Activist investor Nelson Peltz's Trian Fund Management plans to push Solventum (SOLV.N), opens new tab for further business separations following the company's $4.1 billion ...

L.P. (“Trian”), which beneficially owns ~5% of Solventum Corporation (NYSE: SOLV) (“Solventum” or the “Company”) and is the Company’s largest active shareholder, commented on ...

Trian, which owns around 5% of Solventum's shares and is the largest active shareholder, also said divestitures could accelerate the company's ability to reduce debt. Contract drug manufacturer Thermo ...

Nelson Peltz’s firm has held a roughly 5% stake in Solventum since the middle of last year. Solventum, which sells healthcare products, was spun out from 3M in April 2024.

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. ("Trian”), which beneficially owns ~5% of Solventum Corporation (NYSE: SOLV) ("Solventum” or the "Company”) and is the Company's ...

“Trian commends Solventum on the announced sale of its Purification & Filtration business and believes this is an important first step in the Company’s value creation journey. We believe that part of ...